Genocea Biosciences Inc. buy Quitte
Summary
This prediction ended on 22.05.19 with a price of €4.12. The prediction for Genocea Biosciences Inc. disappointed with a performance of -22.84%. Quitte has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | -3.173% | 1.229% | 2.539% | 51.993% |
| iShares Nasdaq 100 | -1.006% | 0.381% | 32.247% | 87.194% |
| iShares Nikkei 225® | -3.600% | 1.005% | 59.535% | 72.473% |
| iShares S&P 500 | 0.214% | 2.924% | 24.524% | 69.844% |
Comments by Quitte for this prediction
In the thread Genocea Biosciences Inc. diskutieren
geh wieder rein
Quitte stimmt am 08.04.2019 dem Buy-Gesamtsentiment mit dem Kursziel 1.0$ zu.
Stopped prediction by Quitte for Genocea Biosciences Inc.
Genocea Biosciences Inc.
05.01.21
05.01.22
06.01.22
Genocea Biosciences Inc.
05.06.18
05.12.18
05.12.18